BiotechTube
Iris Medicine

Iris Medicine

Cambridge, United States· Est.
irismedicine.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Iris Medicine is a private, preclinical-stage biotech founded in 2020 and based in Cambridge, USA, focused on developing allele-selective RNA therapies for repeat expansion disorders. Its core technology, small binding RNA (sbRNA), leverages cooperative binding to selectively inhibit mutant transcripts while sparing healthy ones, using a non-viral delivery system. The company's initial pipeline targets Huntington’s Disease, C9orf72 ALS, and Spinocerebellar Ataxias, aiming to address a large family of diseases with high unmet need. Backed by experienced life science investors and advisors, including pioneers from the RNAi field, Iris is positioned to advance a potentially transformative 'pipeline-in-a-product' platform.

NeurologyOphthalmology

Technology Platform

Small binding RNA (sbRNA): a novel RNA modality using short, ~20nt RNAs that bind cooperatively to target mRNA for allele-selective inhibition, delivered via a non-viral system.

Opportunities

The repeat expansion disorder market represents over twenty diseases with high unmet need and no disease-modifying therapies, offering a multi-billion dollar opportunity.
The 'pipeline-in-a-product' potential of targeting repeat sequences could allow one sbRNA construct to treat multiple disorders, creating significant R&D efficiency.
A successful non-viral, redosable platform would be highly differentiated in the genetic medicine field.

Risk Factors

The core scientific premise of cooperative, allele-selective binding remains unproven in vivo, and delivering RNA therapeutics to the central nervous system non-virally is a major technical hurdle.
The company faces intense competition from more advanced RNAi, antisense, and gene editing programs.
As a preclinical, private company, it carries significant financing and execution risk.

Competitive Landscape

Iris competes in the crowded genetic medicine space for neurological diseases, facing well-funded public companies like Alnylam (RNAi), Ionis (ASO), and Biogen, as well as private gene editing firms. Its key differentiators are the claimed allele-selectivity for all patients via repeat targeting and its non-viral, redosable delivery system, which directly addresses limitations of current approaches.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →